234 related articles for article (PubMed ID: 32270710)
1. Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Zimmer AS; Steinberg SM; Smart DD; Gilbert MR; Armstrong TS; Burton E; Houston N; Biassou N; Gril B; Brastianos PK; Carter S; Lyden D; Lipkowitz S; Steeg PS
Future Oncol; 2020 May; 16(14):899-909. PubMed ID: 32270710
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Jenkins S; Zhang W; Steinberg SM; Nousome D; Houston N; Wu X; Armstrong TS; Burton E; Smart DD; Shah R; Peer CJ; Mozarsky B; Arisa O; Figg WD; Mendoza TR; Vera E; Brastianos P; Carter S; Gilbert MR; Anders CK; Connolly RM; Tweed C; Smith KL; Khan I; Lipkowitz S; Steeg PS; Zimmer AS
Clin Cancer Res; 2023 Apr; 29(8):1450-1459. PubMed ID: 36705597
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
de Azambuja E; Zardavas D; Lemort M; Rossari J; Moulin C; Buttice A; D'Hondt V; Lebrun F; Lalami Y; Cardoso F; Sotiriou C; Gil T; Devriendt D; Paesmans M; Piccart-Gebhart M; Awada A
Ann Oncol; 2013 Dec; 24(12):2985-9. PubMed ID: 24013582
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases.
Zhu Y; Fu L; Jing W; Guo D; Kong L; Yu J
Thorac Cancer; 2018 Sep; 9(9):1121-1128. PubMed ID: 29947170
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.
Tian J; Luo Y; Xiang J; Tang J
J Neurooncol; 2017 Nov; 135(2):217-227. PubMed ID: 28726172
[TBL] [Abstract][Full Text] [Related]
6. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
[TBL] [Abstract][Full Text] [Related]
7. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
10. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Lesueur P; Lequesne J; Grellard JM; Dugué A; Coquan E; Brachet PE; Geffrelot J; Kao W; Emery E; Berro DH; Castera L; Goardon N; Lacroix J; Lange M; Capel A; Leconte A; Andre B; Léger A; Lelaidier A; Clarisse B; Stefan D
BMC Cancer; 2019 Mar; 19(1):198. PubMed ID: 30832617
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.
Addeo R; De Rosa C; Faiola V; Leo L; Cennamo G; Montella L; Guarrasi R; Vincenzi B; Caraglia M; Del Prete S
Cancer; 2008 Nov; 113(9):2524-31. PubMed ID: 18798231
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
13. Brain metastases from esophageal cancer: A case report.
Qie S; Ran Y; Yang H; Cui G; Liu M; Sun X; Tian Y; Sun W; Li N; Liu C
Medicine (Baltimore); 2020 Jun; 99(24):e20223. PubMed ID: 32541449
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V; Ferraro GB; Kodack DP; Badeaux M; Shankaraiah RC; Seano G; Kloepper J; Vardam T; Martin JD; Naxerova K; Bezwada D; Qi X; Selig MK; Brachtel E; Duda DG; Huang P; Fukumura D; Engelman JA; Jain RK
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26547932
[TBL] [Abstract][Full Text] [Related]
16. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
17. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases.
Addeo R; Sperlongano P; Montella L; Vincenzi B; Carraturo M; Iodice P; Russo P; Parlato C; Salzano A; Cennamo G; Lombardi A; Sperlongano R; Prete SD; Caraglia M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):603-9. PubMed ID: 22890892
[TBL] [Abstract][Full Text] [Related]
18. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
20. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
Ebert BL; Niemierko E; Shaffer K; Salgia R
Oncologist; 2003; 8(1):69-75. PubMed ID: 12604733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
